Global Gastrointestinal Partnering 2014-2020: Deal Trends, Players and Financials – ResearchAndMarkets.comApril 8, 2020
DUBLIN–(BUSINESS WIRE)–The “Global Gastrointestinal Partnering 2014-2020: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
- Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
- Analysis of Gastrointestinal deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Gastrointestinal deal contract documents
- Comprehensive access to over 390 Gastrointestinal deal records
- The leading Gastrointestinal deals by value since 2014
- Most active Gastrointestinal dealmakers since 2014
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.
- Chapter 1 provides an introduction to the report.
- Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
- Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
- Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
- Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
- Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.
The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
- 4D Pharma
- AB Analitica
- Ab E Discovery
- Adacyte Therapeutics
- ADL Bionatur Solutions
- Advanced Medical German Company of Kuwait
- Aerpio Therapeutics
- Aevi Genomic Medicine
- AIDS Clinical Trials Group
- Akebia Therapeutics
- Akeso Biopharma
- Akkadeas Pharma
- Alimentary Health
- Allen Institute for Brain Science
- Alma Bio Therapeutics
- Alnylam Pharmaceuticals
- Altos Group
- Alvine Pharmaceuticals
- Alvit LCS Pharma
- Amarex Clinical Research
- Americas Hernia Society Quality Collaborative
- Amneal Pharmaceuticals
- Anatara Lifesciences
- Angelini Pharma
- ANI Pharmaceuticals
- Antibe Therapeutics
- Applied Molecular Transport
- Arc Medical Design
- Aries Pharmaceuticals
- Asana Medical
- Ascension Health Ventures
- AscentX Medical
- Asklepion Pharmaceuticals
- Assembly Biosciences
- Astellas Pharma
- Atlantic Healthcare
- Atnahs Pharma
- Aurobindo Pharma
- Australasian Gastro Intestinal Research Foundation
- Aziyo Biologics
- Bausch Health Companies
- Bayer Healthcare
- B Braun
- BC Children’s Hospital
- BDD Pharma
- Beacon Discovery
- Best Choice
- Bill and Melinda Gates Foundation
- Bio-Rad Laboratories
- Biocodex Microbiota Foundation
- BioDelivery Sciences
- BioFire Diagnostics
- Biomecite Diagnostics
- Biomedical Advanced Research and Development Authority
- Biomedica Medizinprodukte
- Bioportugal Quimica Farmaceutica
- BioRap Technologies
- BioStorage Technologies
- Boehringer Ingelheim
- Boston Pharmaceuticals
- Bridge Biotherapeutics
- Bristol-Myers Squibb
- Broad Institute
- Buchang Pharmaceutical
- Calypso Biotech
- Camargo Pharmaceutical Services
- Cambridge Clinical Laboratories
- Cancer Prevention Pharmaceuticals
- Case Western Reserve University
- Casper Pharma
- CB2 Therapeutics
- Cedars-Sinai Medical Center
- Cell Therapy Catapult
- Celsius Therapeutics
- Celtis Pharm
- Centre Hospitalier Rgional Universitaire (CHRU) de Lille
- Charles River Laboratories
- Cheplapharm Arzneimittel
- Children’s Hospital of Philadelphia
- Chinese University of Hong Kong
- CHU Sainte-Justine
- Cilag AG
- Cincinnati Children’s Hospital Medical Center
- Cipher Pharmaceuticals
- CIRCA Scientific
- CJ Corp
- Cleveland Clinic
- Coherus Biosciences
- Commonwealth Laboratories
- Concordia Healthcare
- Concordia Pharmaceuticals
- Connecticut Children’s Medical Center
- Cook Biotech
- Cook Medical
- Cornell University
- Cosmo Pharmaceuticals
- COUR Pharmaceutical
- Crohn’s and Colitis Foundation of America
- CRS Bio
- Curant Health
- CURE Pharmaceutical
- Cyclerion Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- DBV Technologies
- Delphi Genetics
- Dongkook Pharmaceutical
- Dr. Falk Pharma
- Dr. Reddy’s Laboratories
- and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/7hgjrp
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900